MedTrace Logo

Naltrexone for Prolonged Grief Disorder

NCT06140420 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2026-05-18

No results posted yet for this study

Summary

This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.

Conditions

  • Naltrexone HCl 50 MG Oral Tablet
  • Placebo

Interventions

DRUG

Naltrexone Oral Product

Generic, oral tablet.

DRUG

Placebo

Oral Placebo

Sponsors & Collaborators

  • Texas Tech University Health Science Center

    collaborator UNKNOWN

  • Texas Tech University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-02-01
Completion
2025-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140420 on ClinicalTrials.gov